|
End-of-day quote
Other stock markets
|
||
| - GBX | - |
|
| 07-30 | GSK's ViiV Healthcare Highlights New Long-Acting Injectable Data on Cabenuva in HIV Treatment | MT |
| 07-29 | GSK : DZ Bank remains Neutral | ZD |
| Market Cap | 80.42B 107B 93.71B 87.47B 151B 10,281B 154B 1,037B 405B 5,095B 403B 395B 17,561B | P/E 2026 * |
12.8x | P/E 2027 * | 11.7x |
|---|---|---|---|---|---|
| Enterprise Value | 102B 136B 119B 111B 191B 13,026B 196B 1,314B 513B 6,455B 511B 500B 22,252B | EV / Sales 2026 * |
3x | EV / Sales 2027 * | 2.62x |
| Free-Float |
93.18% | Yield 2026 * |
3.47% | Yield 2027 * | 3.64% |
Last Transcript: GlaxoSmithKline plc
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
| Chief Tech/Sci/R&D Officer | - | 01/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 68 | 01/09/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.87% | +2.94% | +49.73% | +163.92% | 1,089B | |
| -0.45% | +5.95% | +59.75% | +52.18% | 643B | |
| +0.04% | +2.81% | +39.67% | +74.54% | 465B | |
| -1.69% | +8.36% | +38.80% | +34.26% | 359B | |
| -0.51% | +3.35% | +39.00% | +43.76% | 303B | |
| +1.50% | +5.14% | +21.72% | +18.77% | 267B | |
| +0.79% | +4.32% | -25.07% | -36.02% | 226B | |
| -1.39% | +5.84% | +28.66% | +64.00% | 212B | |
| -1.18% | +1.88% | +17.43% | +72.69% | 167B | |
| Average | -0.63% | +5.07% | +29.96% | +54.23% | 414.57B | |
| Weighted average by Cap. | -0.68% | +5.14% | +39.10% | +79.01% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.97B 45.4B 39.58B 36.95B 63.74B 4,342B 65.24B 438B 171B 2,152B 170B 167B 7,418B | 35.64B 47.65B 41.53B 38.77B 66.88B 4,557B 68.46B 459B 180B 2,258B 179B 175B 7,784B |
| Net income | 6.39B 8.54B 7.45B 6.95B 11.99B 817B 12.27B 82.38B 32.19B 405B 32.05B 31.38B 1,396B | 6.95B 9.3B 8.1B 7.56B 13.05B 889B 13.36B 89.65B 35.03B 441B 34.87B 34.15B 1,519B |
| Net Debt | 21.48B 28.71B 25.03B 23.36B 40.3B 2,746B 41.25B 277B 108B 1,361B 108B 105B 4,690B | 12.91B 17.25B 15.04B 14.04B 24.22B 1,650B 24.79B 166B 65.01B 818B 64.71B 63.37B 2,818B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
